Chronicles of a Biosimilar Production Facility 

Biologic restorative items created through rDNA innovation as recombinant protein-based solutions that have been in clinical use since the mid-1980s as unique biopharmaceuticals have extraordinarily added to the treatment of extreme metabolic and degenerative infections. The late close of the information assurance or licenses for the greater part of them made open doors for the advancement of duplicate adaptations of unique biopharmaceuticals with comparative biologic movement (named biosimilars). Generation of these new items is relied upon to take care of overall demand, advance market rivalry, keep up the impetuses for development, and maintain the human services frameworks.

  • Analysis of the Biosimilar Development Pipeline
  • Physicochemical Biosimilar Comparability Studies
  • Biosuperior Development Strategies

Related Conference of Chronicles of a Biosimilar Production Facility 

October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
February 28-March 01, 2019

Global Pharmaceutical & Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
August 5-6, 2019

13th Asian Biologics and Biosimilars Congress

Melbourne, Australia

Chronicles of a Biosimilar Production Facility  Conference Speakers

Recommended Sessions

Related Journals

Are you interested in